SCHEMBL6072061

SCHEMBL6072061

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1ccc(C(=O)O)c(NCc3ccc(OC)cc3)c1)=NC(C)(C)C2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
ASPH Q12797 2/20 0.40
KDM8 Q8N371 2/20 0.40
RIOX2 Q8IUF8 1/20 0.40
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ACP1 P24666 1/20 0.33
IDO1 P14902 1/20 0.33
BLM P54132 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ACLY P53396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072844 0.93 ACLY (0.41) KDM4EALDH1A1GAATSHRSMN1; SMN2
SCHEMBL6072191 0.93 ACLY (0.38) KDM4EASPHKDM8RIOX2ALDH1A1
SCHEMBL6072164 0.92 ACLY (0.38) KDM4EALDH1A1GAAALOX15TSHR
SCHEMBL6071950 0.90 RXRA (0.32) KDM4EALDH1A1GAAHSD17B10ACLY
SCHEMBL6072284 0.89 IDO1 (0.33) KDM4EALDH1A1TSHRSMN1; SMN2HTT
SCHEMBL6071796 0.88 ALDH1A1 (0.35) KDM4EALDH1A1GAAPOLBMEN1
SCHEMBL6071890 0.88 POLB (0.36) KDM4EALDH1A1GAASMN1; SMN2POLB
SCHEMBL6072050 0.88 KDM4E (0.42) KDM4EASPHKDM8ALDH1A1GAA
SCHEMBL6072340 0.88 MAPT (0.35) KDM4EALDH1A1GAATSHRSMN1; SMN2
SCHEMBL6072162 0.87 MKNK2 (0.42) KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A KDM4E 358/4885ASPH 778/4885KDM8 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.